Clinical Trials
35 trialsKANDLELIT-001
Merck Sharp & Dohme LLC
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Jiangsu HengRui Medicine Co., Ltd.
Study of GS-2426 in Participants With Advanced Solid Tumors
Gilead Sciences
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
HighField Biopharmaceuticals Corporation
FAK Inhibitor in Patients With Advanced Solid Tumors
InxMed (Shanghai) Co., Ltd.
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
TCRx Therapeutics Co.Ltd
AMT-676 in Patients With Advanced Solid Tumors
Multitude Therapeutics Inc.
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
Foresight Therapeutics (Hefei) Co., Ltd.
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
SOLID-NK
Beijing Biotech
A Study of SYS6051 in Subjects With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
A Study of SIGX1094R in Patients With Advanced Solid Tumors
Signet Therapeutics
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
SKB118 Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
SKB410 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Samsung Bioepis Co., Ltd.
A Study of SKB315 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of SKB518 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKB445 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKB565 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
DOMISOL
Domain Therapeutics SA
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Pyxis Oncology, Inc